Literature DB >> 3711554

Late and immediate systemic-allergic reactions to inhalant allergen immunotherapy.

M A Greenberg, C R Kaufman, G E Gonzalez, C D Rosenblatt, L J Smith, R J Summers.   

Abstract

Systemic-allergic reactions to allergen immunotherapy were prospectively studied in four allergy treatment centers to assess frequency and specific attributes of these episodes relative to several variables. A total of 20,588 extract injections were administered to 628 patients. Forty-two patients experienced a systemic reaction (7%). Fifty-two systemic reactions occurred in total. Eight patients accounted for 18 of the reactions. Late systemic reactions, occurring from 35 minutes to 6 hours after injection, accounted for 38% of all reactions. Extracts containing only pollen antigens were more commonly associated with immediate and late systemic reactions relative to other extracts (p less than 0.001 and p less than 0.01, respectively). There were no significant reaction-rate differences whether immunotherapy was at maintenance or increasing doses or if the time of injection was during a pollinating or nonpollinating season. The most common clinical manifestations of the systemic reactions were generalized pruritus and urticaria. We conclude that patients receiving extracts containing only pollen antigens have increased systemic-allergic reaction rates. A subgroup of patients are at risk for recurrent reactions. Finally, late systemic reactions to immunotherapy are not rare events and pose a definite risk to the individual patient.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3711554     DOI: 10.1016/0091-6749(86)90385-4

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  9 in total

Review 1.  Allergic emergencies in the physician's office.

Authors:  P A Greenberger
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 8.667

Review 2.  The risk and management of anaphylaxis in the setting of immunotherapy.

Authors:  Phil Lieberman
Journal:  Am J Rhinol Allergy       Date:  2012 Nov-Dec       Impact factor: 2.467

Review 3.  Late-phase IgE-mediated reactions.

Authors:  R F Lemanske; M Kaliner
Journal:  J Clin Immunol       Date:  1988-01       Impact factor: 8.317

Review 4.  Minimising the risks of allergen-specific injection immunotherapy.

Authors:  H J Malling
Journal:  Drug Saf       Date:  2000-10       Impact factor: 5.606

Review 5.  Fatalities following allergen immunotherapy.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2004-10       Impact factor: 8.667

Review 6.  Complexities of diagnosis and treatment of allergic respiratory disease in the elderly.

Authors:  Paula J Busse; Kiran Kilaru
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 7.  Safety considerations in assessing the role of immunotherapy in allergic disorders.

Authors:  J Bousquet; F B Michel
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

8.  An EAACI "European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)": the methodology.

Authors:  Moises A Calderón; Pablo Rodríguez Del Río; Carmen Vidal; Jocelyne Just; Oliver Pfaar; Allan Linneberg; Pascal Demoly
Journal:  Clin Transl Allergy       Date:  2014-07-21       Impact factor: 5.871

Review 9.  Breathing Better Through Bugs: Asthma and the Microbiome.

Authors:  Alexander J Adami; Sonali J Bracken
Journal:  Yale J Biol Med       Date:  2016-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.